Organization
Canadian Generic Pharmaceutical Association (CGPA)
- Meetings this Parliament
- 17
- With MPs
- 4
- Since Nov 2021
- 56
- Active registrations
- 1
Most recent reported meeting: Sep 24, 2026.
Lobbying by Canadian Generic Pharmaceutical Association (CGPA): its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingWho they meet
Since the current Parliament opened.
MPs
- Maggie Chi Liberal 1
- Marjorie Michel Liberal 1
- Raquel Dancho Conservative 1
- Mélanie Joly Liberal 1
Institutions
- Health Canada (HC)10
- Innovation, Science and Economic Development Canada (ISED)4
- House of Commons2
- Global Affairs Canada (GAC)1
- Finance Canada (FIN)1
Registrations in effect
In-house (organization) In effect since Jun 23, 2025
Filed by James Keon, PRESIDENT
Lobbyists
-
James Keon · President
Former public office holder
Formerly Acting Director General, Consumer Affairs, Industry Canada (1994–1994)
Formerly Regional Director, B.C. and Yukon, Consumer and Corporate Affairs (1991–1993)
Formerly Director, Intellectual Property, Consumer and Corporate Affairs (1988–1991)
Formerly Senior Analyst, Consumer Affairs, Consumer and Corporate Affairs (1987–1988)
- Jeff Connell · Vice President, Corporate Affairs
-
Jody Cox · Vice President, Federal and International Affairs
Former public office holder
Formerly Special Assistant, Communications, Progressive Conservative's Leader Office, House of Commons (2000–2001)
- Kristin Willemsen · Vice President, Scientific and Regulatory Affairs
Institutions they may lobby: CUSMA Secretariat, Canada Border Services Agency (CBSA), Canadian Heritage (PCH), Canadian International Trade Tribunal (CITT), Competition Bureau Canada (COBU), Employment and Social Development Canada (ESDC), Environment and Climate Change Canada (ECCC), Export Development Canada (EDC), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), Intergovernmental Affairs Secretariat (IGA), National Defence (DND), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Public Safety Canada (PS), Public Services and Procurement Canada (PSPC), Senate of Canada, Transport Canada (TC), Treasury Board Of Canada Secretariat (TBS), Veterans Affairs Canada (VAC)
What they're lobbying on (19)Hide details
- Innovation, Science and Economic Development Canada (ISED) Innovation Agenda regarding the need for a balanced intellectual property regime and the important role competition plays in encouraging innovation.
- Provide input into policy discussions with respect to the implementation of a national pharmacare program.
- Provide input into the Government of Canada's negotiations regarding trade negotiations with respect to pharmaceuticals, counterfeit medicines, and intellectual property.
- Provide input into the Canada-US trade relationship as it pertains to medicines, including the impact of tariffs on medicines and medicine manufacturing inputs for the Canadian healthcare system, patients and industry.
- Provide input into the Canada-United States-Mexico Agreement (CUSMA).
- To encourage the Government of Canada to continue to participate in truly international discussions with respect to effective measures to combat substandard and falsified medicines in Canada and around the world.
- Seeking harmonization of regulatory regimes and administrative processes nationally and internationally.
- Providing input with respect to the approval pathway for biosimilar medicines by Health Canada.
- Provide input into the Patented Medicine Prices Review Board (PMPRB) consultations regarding its Policies, Guidelines and Procedures.
- Provide input into the modernization of the Food and Drugs Act and related Regulations, Guidelines and Policies as they pertain to pharmaceuticals.
- Proposals to enhance transparency of the Health Canada Reconsiderations Policy for drug submissions.
- Proposals related to Health Canada's Identical Medicinal Ingredient Policy.
- Participation in Competition Bureau consultations with respect to pharmaceuticals.
- Participate in Government of Canada consultations with respect to the Regulatory Cooperation Council.
- Health Canada with respect to user fees for therapeutic product regulatory programs.
- Health Canada with respect to the process for the approval and renewal of foreign sites for Drug Establishment License (DEL) holders. Related guidance documents include the Guidance on Evidence to Demonstrate Drug GMP Compliance of Foreign Sites (GUI-0080), the Guidance on Drug Establishment Licences and Drug Establishment Licensing Fees (GUI-0002) and the Guidance on Good Manufacturing Practices for Active Pharmaceutical Ingredients (GUI-0104).
- Health Canada with respect to its Regulatory Systems Review for Therapeutic Products.
- Health Canada regarding the development of a national pharmacare strategy.
- Discussions with ISED towards a national strategy for the biomanufacturing and the life sciences sector.
Registration 776966-548-56. Look it up in the official Registry
Reported meetings
Spreadsheet-
Reported by James Keon · In-house (organization)
- Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
- Sven Schirmer · Senior Advisor, Health Canada (HC)
Health Canada with respect to its Regulatory Systems Review for Therapeutic Products. Read more
Provide input into the modernization of the Food and Drugs Act and related Regulations, Guidelines and Policies as they pertain to pharmaceuticals.
Provide input into the Canada-US trade relationship as it pertains to medicines, including the impact of tariffs on medicines and medicine manufacturing inputs for the Canadian healthcare system, patients and industry.
-
Reported by James Keon · In-house (organization)
- Raquel Dancho · Member of Parliament
Discussions with ISED towards a national strategy for the biomanufacturing and the life sciences sector. Read more
Health Canada with respect to its Regulatory Systems Review for Therapeutic Products.
Provide input into the Canada-US trade relationship as it pertains to medicines, including the impact of tariffs on medicines and medicine manufacturing inputs for the Canadian healthcare system, patients and industry.
-
Reported by James Keon · In-house (organization)
- Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
- Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
- Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
Provide input into the Canada-US trade relationship as it pertains to medicines, including the impact of tariffs on medicines and medicine manufacturing inputs for the Canadian healthcare system, patients and industry. Read more
Provide input into the modernization of the Food and Drugs Act and related Regulations, Guidelines and Policies as they pertain to pharmaceuticals.
-
Reported by James Keon · In-house (organization)
- Martin Moen · Associate Assistant Deputy Minister, Trade Policy and Negotiations, Global Affairs Canada (GAC)
Provide input into the Canada-US trade relationship as it pertains to medicines, including the impact of tariffs on medicines and medicine manufacturing inputs for the Canadian healthcare system, patients and industry. Read more
Provide input into the Canada-United States-Mexico Agreement (CUSMA).
-
Reported by James Keon · In-house (organization)
- Paul Moen · Chief of Staff, Innovation, Science and Economic Development Canada (ISED)
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
Innovation, Science and Economic Development Canada (ISED) Innovation Agenda regarding the need for a balanced intellectual property regime and the important role competition plays in encouraging innovation. Read more
Discussions with ISED towards a national strategy for the biomanufacturing and the life sciences sector.
Provide input into the modernization of the Food and Drugs Act and related Regulations, Guidelines and Policies as they pertain to pharmaceuticals.
Provide input into the Canada-US trade relationship as it pertains to medicines, including the impact of tariffs on medicines and medicine manufacturing inputs for the Canadian healthcare system, patients and industry.
-
Reported by James Keon · In-house (organization)
- Maggie Chi · Parliamentary Secretary to the Minister of Health
- Nora Draper · Parliamentary Secretary Assistant, Health Canada (HC)
Provide input into the modernization of the Food and Drugs Act and related Regulations, Guidelines and Policies as they pertain to pharmaceuticals. Read more
Discussions with ISED towards a national strategy for the biomanufacturing and the life sciences sector.
Provide input into the Canada-US trade relationship as it pertains to medicines, including the impact of tariffs on medicines and medicine manufacturing inputs for the Canadian healthcare system, patients and industry.
-
Reported by James Keon · In-house (organization)
- Philip Jennings · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Discussions with ISED towards a national strategy for the biomanufacturing and the life sciences sector. Read more
Innovation, Science and Economic Development Canada (ISED) Innovation Agenda regarding the need for a balanced intellectual property regime and the important role competition plays in encouraging innovation.
Provide input into the modernization of the Food and Drugs Act and related Regulations, Guidelines and Policies as they pertain to pharmaceuticals.
Provide input into the Canada-US trade relationship as it pertains to medicines, including the impact of tariffs on medicines and medicine manufacturing inputs for the Canadian healthcare system, patients and industry.
-
Reported by James Keon · In-house (organization)
- Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
Provide input into the modernization of the Food and Drugs Act and related Regulations, Guidelines and Policies as they pertain to pharmaceuticals. Read more
Provide input into the Canada-US trade relationship as it pertains to medicines, including the impact of tariffs on medicines and medicine manufacturing inputs for the Canadian healthcare system, patients and industry.
Provide input into the Canada-United States-Mexico Agreement (CUSMA).
-
Reported by James Keon · In-house (organization)
- Justine Frame · Policy Advisor, Health Canada (HC)
Provide input into the modernization of the Food and Drugs Act and related Regulations, Guidelines and Policies as they pertain to pharmaceuticals. Read more
Provide input into the Canada-US trade relationship as it pertains to medicines, including the impact of tariffs on medicines and medicine manufacturing inputs for the Canadian healthcare system, patients and industry.
-
Reported by James Keon · In-house (organization)
- Marjorie Michel · Minister of Health, Health Canada (HC)
Health Canada with respect to its Regulatory Systems Review for Therapeutic Products. Read more
Provide input into the modernization of the Food and Drugs Act and related Regulations, Guidelines and Policies as they pertain to pharmaceuticals.
-
Reported by James Keon · In-house (organization)
- Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
- Sven Schirmer · Senior Advisor, Health Canada (HC)
Health Canada with respect to its Regulatory Systems Review for Therapeutic Products. Read more
Innovation, Science and Economic Development Canada (ISED) Innovation Agenda regarding the need for a balanced intellectual property regime and the important role competition plays in encouraging innovation.
Provide input into the modernization of the Food and Drugs Act and related Regulations, Guidelines and Policies as they pertain to pharmaceuticals.
Provide input into the Canada-US trade relationship as it pertains to medicines, including the impact of tariffs on medicines and medicine manufacturing inputs for the Canadian healthcare system, patients and industry.
-
Reported by James Keon · In-house (organization)
- Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
- Margaret Zimmermann · Chief of Staff, Health Canada (HC)
Health Canada with respect to its Regulatory Systems Review for Therapeutic Products. Read more
Provide input into the modernization of the Food and Drugs Act and related Regulations, Guidelines and Policies as they pertain to pharmaceuticals.
-
Reported by James Keon · In-house (organization)
- Greg Orencsak · Deputy Minister, Health Canada (HC)
- Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
Provide input into the modernization of the Food and Drugs Act and related Regulations, Guidelines and Policies as they pertain to pharmaceuticals. Read more
Health Canada with respect to its Regulatory Systems Review for Therapeutic Products.
Seeking harmonization of regulatory regimes and administrative processes nationally and internationally.
Innovation, Science and Economic Development Canada (ISED) Innovation Agenda regarding the need for a balanced intellectual property regime and the important role competition plays in encouraging innovation.
-
Reported by James Keon · In-house (organization)
- Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
Discussions with ISED towards a national strategy for the biomanufacturing and the life sciences sector. Read more
Innovation, Science and Economic Development Canada (ISED) Innovation Agenda regarding the need for a balanced intellectual property regime and the important role competition plays in encouraging innovation.
Health Canada with respect to its Regulatory Systems Review for Therapeutic Products.
Provide input into the Canada-US trade relationship as it pertains to medicines, including the impact of tariffs on medicines and medicine manufacturing inputs for the Canadian healthcare system, patients and industry.
Seeking harmonization of regulatory regimes and administrative processes nationally and internationally.
-
Reported by James Keon · In-house (organization)
- Mélanie Joly · Minister of Industry and Minister Responsible for the Economic Development for Quebec Regions, Innovation, Science and Economic Development Canada (ISED)
- Paul Moen · Chief of Staff, Innovation, Science and Economic Development Canada (ISED)
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
Innovation, Science and Economic Development Canada (ISED) Innovation Agenda regarding the need for a balanced intellectual property regime and the important role competition plays in encouraging innovation. Read more
Health Canada with respect to its Regulatory Systems Review for Therapeutic Products.
Provide input into the Canada-US trade relationship as it pertains to medicines, including the impact of tariffs on medicines and medicine manufacturing inputs for the Canadian healthcare system, patients and industry.
-
Reported by James Keon · In-house (organization)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Discussions with ISED towards a national strategy for the biomanufacturing and the life sciences sector. Read more
Innovation, Science and Economic Development Canada (ISED) Innovation Agenda regarding the need for a balanced intellectual property regime and the important role competition plays in encouraging innovation.
Health Canada with respect to user fees for therapeutic product regulatory programs.
Health Canada with respect to its Regulatory Systems Review for Therapeutic Products.
Provide input into the Canada-US trade relationship as it pertains to medicines, including the impact of tariffs on medicines and medicine manufacturing inputs for the Canadian healthcare system, patients and industry.
-
Reported by James Keon · In-house (organization)
- Greg Orencsak · Deputy Minister, Health Canada (HC)
- Krista Urchenko · Senior Advisor, Health Canada (HC)
- Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
Health Canada with respect to its Regulatory Systems Review for Therapeutic Products. Read more
Providing input with respect to the approval pathway for biosimilar medicines by Health Canada.
Health Canada with respect to user fees for therapeutic product regulatory programs.
Innovation, Science and Economic Development Canada (ISED) Innovation Agenda regarding the need for a balanced intellectual property regime and the important role competition plays in encouraging innovation.
Provide input into the Canada-US trade relationship as it pertains to medicines, including the impact of tariffs on medicines and medicine manufacturing inputs for the Canadian healthcare system, patients and industry.
-
Reported by James Keon · In-house (organization)
- Aaron Fowler · Chief Trade Negotiator and Associate Assistant Deputy Minister, Global Affairs Canada (GAC)
Provide input into the Canada-US trade relationship as it pertains to medicines, including the impact of tariffs on medicines and medicine manufacturing inputs for the Canadian healthcare system, patients and industry. Read more
Provide input into the Canada-United States-Mexico Agreement (CUSMA).
-
Reported by James Keon · In-house (organization)
- Jeremy Bruce · Director, Canada-US Relations, Global Affairs Canada (GAC)
- Nicholas Lovrics · Senior Advisor, Parliamentary Affairs and Issues Management, Global Affairs Canada (GAC)
Provide input into the Canada-US trade relationship as it pertains to medicines, including the impact of tariffs on medicines and medicine manufacturing inputs for the Canadian healthcare system, patients and industry. Read more
-
Reported by James Keon · In-house (organization)
- Eshan Naik · Deputy Chief of Staff and Director of Policy, Health Canada (HC)
Provide input into the Canada-US trade relationship as it pertains to medicines, including the impact of tariffs on medicines and medicine manufacturing inputs for the Canadian healthcare system, patients and industry. Read more
-
Reported by James Keon · In-house (organization)
- Eshan Naik · Deputy Chief of Staff and Director of Policy, Health Canada (HC)
Provide input into the Canada-US trade relationship as it pertains to medicines, including the impact of tariffs on medicines and medicine manufacturing inputs for the Canadian healthcare system, patients and industry. Read more
-
Reported by James Keon · In-house (organization)
- Mark Holland · Minister of Health, Health Canada (HC)
- Michelle Boudreau · Associate Assistant Deputy Minister, Health Canada (HC)
- Linsey Hollett · A/Assistant Deputy Minister, Health Canada (HC)
Provide input into the Canada-US trade relationship as it pertains to medicines, including the impact of tariffs on medicines and medicine manufacturing inputs for the Canadian healthcare system, patients and industry. Read more
-
Reported by James Keon · In-house (organization)
- Jade Mallette · Director of Parliamentary Affairs, Health Canada (HC)
Health Canada regarding the development of a national pharmacare strategy.
-
Reported by James Keon · In-house (organization)
- Michelle Boudreau · Associate Assistant Deputy Minister, Health Canada (HC)
Providing input with respect to the approval pathway for biosimilar medicines by Health Canada.
-
Reported by James Keon · In-house (organization)
- Michelle Boudreau · Associate Assistant Deputy Minister, Health Canada (HC)
Health Canada regarding the development of a national pharmacare strategy.
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.